B. Riley Securities Reiterates Buy on Cognition Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Mayank Mamtani has reiterated a Buy rating on Cognition Therapeutics (NASDAQ:CGTX) and maintained a $5 price target on the stock.
March 28, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B. Riley Securities reiterates a Buy rating on Cognition Therapeutics with a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst firm like B. Riley Securities could instill confidence among investors and potentially lead to a positive short-term impact on CGTX's stock price. Analyst ratings often influence investor perception and can lead to price movements.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90